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Abstract Despite the availability of effective pharmaco-
logical treatments to aid the control of blood pressure, the
global rate of uncontrolled blood pressure remains high. As
such, further measures are required to improve blood pressure
control. Recently, several national and international guidelines
for the management of hypertension have been published.
These aim to provide easily accessible information for
healthcare professionals and patients to aid the diagnosis and
treatment of hypertension. In this review, we have compared
new and current guidelines from the American and Interna-
tional Societies of Hypertension; the American Heart Asso-
ciation, American College of Cardiology and the US Center
for Disease Control and Prevention; the panel appointed to the
Eighth Joint National Committee; the European Societies of
Hypertension and Cardiology; the French Society of Hyper-
tension; the Canadian Hypertension Education Program; the
National Institute for Health and Clinical Excellence (UK); the
Taiwan Society of Cardiology and the Chinese Hypertension
League. We have identified consensus opinion regarding best
practises for the management of hypertension and have
highlighted any discrepancies between the recommendations.
In general there is good agreement between the guidelines,
however, in some areas, such as target blood pressure ranges
for the elderly, further trials are required to provide sufficient
high-quality evidence to form the basis of recommendations.
Key Points
The recently published updates to European,
American, Canadian, French, UK, Chinese and
Taiwanese guidelines for hypertension broadly
provide a consensus on the best practise for
diagnosing and management of hypertension.
There are some areas, such as treatment goals for the
elderly and for patients with diabetes, where there
are discrepancies in the recommendations due to a
lack of consistent and high-quality evidence to form
the basis of recommendations.
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The worldwide prevalence of hypertension is rising; the
number of cases rose from 600 million in 1980 to 1 billion
in 2008 [1]. Although hypertension itself is generally
asymptomatic, it is one of the key risk factors for cardio-
vascular disease (CVD). Hypertension accounts for
approximately 45 % of deaths due to heart disease and
51 % of deaths due to stroke [1]. Complications of
hypertension are thought to cause 9.4 million deaths each
year, and without further action the World Health Orga-
nization (WHO) has predicted this number will increase
[1]. It has been predicted that by 2030 nearly a quarter of
all deaths worldwide will be due to CVD [1]. However, if
hypertension was controlled in all patients, a substantial
decrease in CV events would be seen; for example, in the
UK it has been predicted that the incidence of stroke would
be reduced by 28–44 % and ischaemic heart disease by
20–35 % [2].
Effective treatments to control blood pressure (BP) are
available but measures need to be taken to ensure their use
is maximised in the required patient groups. To achieve
this, effective multifactorial programmes with strategies to
manage blood pressure are being sought. As part of this
programme, clear evidence-based guidelines that can be
readily implemented across diverse populations are
required. Indeed, clinical guidelines are considered the
intersection between evidence and clinical practice to
improve patients’ CV outcomes [3].
In 2013, a number of national and international hyper-
tension guidelines were updated. Although these guidelines
have evolved to reflect new evidence and best practice, the
objective remains unequivocal: to develop recommenda-
tions, based on clinical evidence, to aid the diagnosis,
treatment and management of hypertension. In light of the
recent updates, we felt it important to review and compare
the latest updates with currently utilised regional guide-
lines. The review will discuss hypertension guidelines from
the US including those from the Eighth Joint National
Committee (JNC 8) (updated 2013) [3–5], regularly
updated Canadian recommendations (annual non-radical
updates) [6], European (European Societies of Hyperten-
sion and Cardiology (ESH/ESC]) guidelines (updated in
2013) [7], UK (National Institute for Health and Clinical
Excellence [NICE); last updated in 2011) [8], France
(updated in 2013) [9], Taiwan (last updated in 2010
[pending update in 2014]) [10] and China (last updated in
2010) [11]. Table 1 [3–11] provides an overview of the
development and aims of these guidelines.
All the guidelines were produced by committees of
healthcare professionals and scientists with a broad range
of expertise in the field of hypertension and principally
used evidence from systematic reviews of randomised
control trials (RCT) [3–11]. Notably, NICE also has
patients on the panel to support the development and
updating of their clinical practice guidelines [8]. The
guidelines were developed as a means of improving and
standardising the management of hypertension within their
jurisdictions. It is important to note that all the guidelines
state that they are not mandatory, but aim to help facilitate
the physicians’ treatment decisions on a case by case basis.
By comparing these guidelines, we aim to identify the
major differences in recommendations and establish where
there is consensus on best practice for hypertension man-
agement (summarised in Table 2). Specifically, the review
will focus on recommendations for the utilisation of diag-
nostic tools, the BP levels defined for initiating treatment,
target BP levels, and the proposed non-pharmacological
and pharmacological interventions. Further to this analysis,
we will collectively provide our expert opinion on the
future development of guidelines and how best to imple-
ment these into clinical practice.
2 Tools for Diagnosing Hypertension and Monitoring
Blood Pressure
Accurate diagnosis of hypertension and the identification of
other CV risk factors is essential to identify patients that
will likely benefit from treatment to control BP [1]. Based
on office BP measurements, all the guidelines utilise a
common definition of stage 1 hypertension as clinic seated
systolic (SBP)/diastolic (DBP) C140/90 mmHg and stage 2
hypertension as C160/100 mmHg [3–11]. Where stated,
the guidelines are in agreement regarding the use of lower
BP measurements for defining hypertension based on
ambulatory (ABPM) or home blood pressure monitoring
(HBPM). With the exception of the American Heart Asso-
ciation (AHA), American College of Cardiology (ACC), the
Center for Disease Control and Prevention (CDC) and JNC
8 guidelines, all the guidelines discuss methods for diag-
nosing and monitoring BP [3, 4]. With the exception of the
NICE and Canadian Hypertension Education Program
(CHEP) guidelines, the consensus is that a diagnosis of
hypertension should be based on multiple office BP mea-
surements, taken on at least two separate visits, 1–4 weeks
apart [5, 7, 9–11]. The CHEP guidelines are more stringent
and suggest that if SBP is 140–160 mmHg or DBP
90–100 mmHg, then office BP should be measured on four
to five separate occasions, or self-monitoring/ABPM should
be used before diagnosis is made [6].
Although the use of both ABPM and HBPM are
recognised as effective diagnostic tools that are becoming
more widely used, only the CHEP and NICE guidelines
currently recommend that a diagnosis can be made based
on either of these measurements [6, 8]; for all other
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guidelines office BP is still regarded as the gold standard
for diagnosis [3–5, 7, 9–11]. Uniquely, the NICE guide-
lines recommend that office BP is used to initially screen
for hypertension, with ABPM (or HBPM if patients are
unable or unwilling to use ABPM) then used to confirm the
diagnosis [8]. French and Taiwan guidelines recommend
the use of self-monitoring to confirm office BP measure-
ments before diagnosis is made [9, 10], while other
guidelines (American and International Societies of
Hypertension [ASH/ISH] and ESH/ESC) recommend self-
monitoring for borderline cases, when variable office BP
measurements are recorded or when white-coat
hypertension is suspected [5, 7]. The ESH/ESC and NICE
guidelines state that ABPM is the preferred method of self-
monitoring for diagnosis [7, 8], although French and ESH/
ESC guidelines state that HBPM is more suitable than
ABPM for monitoring BP subsequent to diagnosis [7, 9]. In
Taiwan and Canada, the cost of ABPM is not reimbursed
by the National Health Insurance System, therefore its use
is limited and HBPM is more widely used [10]; this is an
example of how healthcare resource and financial con-
straints can enforce differences in recommendations. As
the cost of ABPM decreases its use is likely to become
more commonplace. Indeed, a UK-based study
Table 2 Summary highlighting the major consensus findings and discrepancies between guidelines
Consensus opiniona Discrepancies
Measuring BP Multiple office BP measurements are the gold
standard for diagnosis
NICE states that ABPM is the gold standard for diagnosis
before initiating therapy—daytime average BP [135/85
defined as hypertensionSelf-monitoring can aid diagnosis and long-term BP
monitoring
Target office BP \140/90 mmHg for general population Differing targets for elderly
CHEP, Taiwan and EHC/ESC recommend lower target for
patients with diabetes or CKD
Health behaviour
modifications
Important role in combination with pharmacological
treatment
Initiation before (ASH/ISH, AHA/ACC/CDC, ESH/ESC,
NICE, France) or in conjunction (China, Taiwan), with
pharmacological treatmentFocus on the same factors e.g., diet and exercise
Pharmacological
treatment
Individualise treatment to meet patient needs b-Blockers are not advised for treatment of general population
in the JNC 8, ASH/ISH. AHA/ACC/CDC, NICE, Taiwan
guidelines and are restricted to those \60 years of age in
CHEP guidelines
Principally use 4 classes of drugs, diuretics, CCB,
ACEI and ARB
Simplify drug regimens by using long-acting drugs
and SPCs
Gaining BP control as soon as possible improves
persistence
Patient education improves persistence
Regular monitoring is required
Drug combinations Multiple drugs are required in most cases
SPCs can be used when available
ACEI and ARB should not be used in combination
CCB ? thiazide ? ACEI/ARB is the preferred
3-drug combination
SPCs recommended by China and Taiwan guidelines for initial
treatment if more than one drug is required
No consensus on drug class to be used for initial treatment




Specific treatment recommendations are required
for patients with associated comorbidities
–
Treatment of black patients should be initiated with
CCB or thiazide diuretic
b-Blockers should be prescribed for patients with a
history of myocardial infarction, heart failure or
angina pectoris
Treatment algorithms A useful tool for providing simplified treatment
advice
–
AHA/ACC/CDC American Hypertension Association/American College of Cardiology/Centers for Disease Control and Prevention, ASH/ISH
American Society of Hypertension/International Society of Hypertension, CHEP Canadian hypertension education program, ESH/ESC European
Society of Hypertension/European Society of Cardiology, JNC 8 Eighth Joint National Committee, NICE National Institute for Clinical
Excellence (UK), ABPM ambulatory blood pressure monitoring, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor
blocker, BP blood pressure, CCB calcium channel blocker, CKD chronic kidney disease, SPC single pill combination
a Consensus recommendations are those that are presented in the majority of the guidelines, with no conflicting advice presented in the other
guidelines (although the subject may not be discussed)
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investigating the cost effectiveness of using ABPM for
diagnosis concluded that the additional cost of imple-
menting ABPM outweighed the savings made by providing
more accurate diagnosis and treatment [12].
3 Blood Pressure Thresholds for Initiating Treatment
There is some disparity between the guidelines regarding
when drug treatment to control BP should be initiated
(Table 3 [3–11]). The Taiwan guidelines are the only guide-
lines to recommend treatment of patients with high-normal
BP (130–139/80–89 mmHg) if they have additional risk
factors [10]. Both the French and Taiwan guidelines recom-
mend commencing pharmacological treatment of stage 1
patients regardless of other risk factors, whereas the other
guidelines recommend a trial period of health behaviour
modifications to try and control BP without therapy. The
recommended duration of this period varies from several
months in the ESH/ESC guidelines [7], 3 months in the AHA/
ACC/CDC guidelines [4], to 6–12 months in the ASH/ISH
guidelines [5] (NICE guidelines do not specify a time period
[8]). In addition, the French guidelines recommend health
behaviour modifications commence prior to a confirmed
diagnosis of hypertension [9]. The NICE and Canadian rec-
ommendations note that for those at very low risk (the para-
digm being a pre-menopausal female with no other risk
factors, or younger people) with an SBP of \160 mmHg and
DBP \100 mmHg, initiation of antihypertensive therapy can
be deferred. This recommendation is in accordance with their
very low risk for CV complications, subsequent low proba-
bility of benefiting from therapy and that lack of evidence for
treatment in low-risk patients with stage 1 hypertension [6, 8].
With the exception of the ESH/ESC guidelines, all
guidelines recommend commencing pharmacological
treatment of stage 2 patients immediately following diag-
nosis. The ESH/ESC recommend that, even low-risk stage
2 patients undergo a phase of health modifications before
commencing treatment.
Some guidelines provide specific recommendations for
initiating treatment of the elderly. ESH/ESC, NICE and
CHEP suggest that for patients aged C80 years, an SBP
of [160 mmHg should be used as a threshold for initiating
pharmacological intervention [6–8]. JNC 8 guidelines
recommend initiating treatment of patients aged C60 years
if their BP is C150/90 mmHg [3].
4 Target Blood Pressure Levels
4.1 Elderly Patients
All the guidelines have the same target of SBP B140 and
DBP B90 mmHg for the general adult population,
however, some variations exist in the recommendations for
specific groups of patients (Table 4 [3–11]). The AHA/
ACC/CDC and Taiwan guidelines do not contain any
specific BP targets for the elderly, whereas the JNC 8,
ESH/ESC, ASH/ISH, French, NICE, CHEP and China
guidelines suggest that a higher target of \150/90 mmHg
is appropriate based largely on data from the HYVET study
[13]. It is important to note, however, that the definition of
elderly varies between the guidelines: JNC 8 guidelines
class elderly as C60 years of age [3], China as C65 years
of age [11], and the ASH/ISH, French, NICE, CHEP and
ESH/ESC guidelines define it as people C80 years [5, 7–
9]. The ESH/ESC guidelines make this recommendation
with the additional caveat that if the patient is otherwise
considered healthy then a target SBP B140 mmHg is rec-
ommended [7]. It has been reported that the higher target
BP (\150/90 mmHg) for the elderly population (defined
as C60 years of age), recommended by the JNC 8 guide-
lines, was one of the few recommendations where the
committee failed to reach consensus [14]. The majority of
the JNC 8 panel concluded that, as there was no definitive
evidence to determine target BP levels in the elderly,
increasing the target SBP from 140 to 150 mmHg was the
optimum approach [14]. However, a minority group indi-
cated that CVD prevalence in the USA could rise should
this less stringent target be implemented in clinical prac-
tice. The minority group insisted the higher BP target to be
recommended only for those over 80 years of age, in
alignment with the majority of national guidelines [14].
4.2 Patients with Diabetes or Chronic Kidney Disease
The recommended target BP for patients with comor-
bidities has evolved and become less stringent across
the guidelines due to a lack of quality evidence.
Although some guidelines (e.g., ESH/ESC 2007 and
JNC 7 guidelines [15, 16]) have previously advised a
lower target BP (B130/80 mmHg) in patients with
chronic kidney disease (CKD) or diabetes, the majority
of guidelines now state that there is not sufficient evi-
dence to support this recommendation and have deferred
back to a more conservative evidence-based treatment
goal for the general population (B140/90 mmHg). For
example, in the case of patients with diabetes, both the
ESH/ESC and JNC 8 guidelines cite the action to con-
trol cardiovascular risk in diabetes (ACCORD) trial
which showed no additional benefit of lowering
SBP \130 mmHg (although the study was under pow-
ered) [17]. However, based on results of the hyperten-
sion optimal treatment (HOT) [18] and United Kingdom
Prospective Diabetes Study (UKPDS) [19] the ESH/ESC
guidelines suggest a lower target DBP (\85 mmHg) [7].
In contrast, the JNC 8 panel concluded that based on
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these trials there were not sufficient good quality data to
recommend a lower target DBP. This discrepancy may
at least in part be due to the JNC 8 panel focusing on
the effect on mortality whereas ESH/ESC analysed data
regarding all CV events and used post hoc analysis
(which was disregarded by the JNC 8 committee) of
patient subgroups from the HOT trial.
The CHEP and Taiwan guidelines recommend patients
with diabetes should be treated to attain BP of B130/
80 mmHg [6, 10]. This recommendation is based on results
from the HOT study and several recent meta-analyses that
have shown that achieving a lower BP reduces the risk of
stroke without resulting in an increase in myocardial
infarction [18, 20–22].





















































































AHA/ACC/CDC American Hypertension Association/American College of Cardiology/Centers for Disease Control and Prevention, ASH/ISH
American Society of Hypertension/International Society of Hypertension, CHEP Canadian hypertension education program, ESH/ESC European
Society of Hypertension/European Society of Cardiology, JNC 8 Eighth Joint National Committee, NICE National Institute for Clinical
Excellence (UK), SBP systolic blood pressure
a Note that this subject is not discussed in JNC 8 guidelines
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In the case of CKD, only the China, Taiwan and ESH/
ESC (with proteinuria) guidelines recommend a lower
target BP (B130/80 mmHg) [7, 10, 11]. The ESH/ESC
guidelines highlight the lack of clear evidence to support
this target, with recent meta-analyses failing to demon-
strate any benefit from achieving lower BP [23, 24];
however, there is some limited evidence that suggests a
lower target may be beneficial in patients with proteinuria
[7, 25].
5 Health Behaviour Intervention Strategies
All guidelines recommend that health behaviour changes
form part of the treatment of hypertension (Table 5 [3–11,
26]). Although the AHA/ACC/CDC, ESH/ESC, ASH/ISH
and NICE guidelines recommend a period of health
behaviour modifications prior to initiating pharmacological
treatment, in general, health behaviour modifications
should be seen as complementary to drug therapy and not
an alternative [4, 5, 7, 8].
The health behaviour modifications are generally similar
between guidelines, with a focus on a diet rich in fruit and
vegetables and low in saturated fat, regular physical exer-
cise, weight loss, reduced alcohol and sodium consump-
tion, and smoking cessation. The main inconsistency is the
China guidelines recommend increasing potassium intake
(as the typical Chinese diet is low in potassium) [11],
whereas CHEP and NICE guidelines specifically state that
potassium supplementation is not recommended as there is
not sufficient evidence to demonstrate any benefit [6, 8].
Although all guidelines recommend lowering salt
intake, the suggested levels vary. Currently, the average
per-person salt intake is 9–12 g/day and WHO recom-
mends reducing this to \5 g salt (2,000 mg sodium) per
day [1]; the ESH/ESC, NICE, AHA/ACC/CDC, JNC 8,
CHEP, China and Taiwan guidelines all suggest a similar
target [3, 4, 7, 8, 10, 11]. Although the ASH/ISH and
French guidelines suggest reducing salt intake, they do not
suggest a target level [5, 9]. Inconsistencies in salt intake
recommendations may be due to conflicting evidence sur-
rounding the optimal level of dietary salt. Although high
levels of salt have been linked with hypertension and an
increased risk of CVD, some reports suggest low salt intake
may be associated with higher cardiovascular mortality and
adverse health outcomes (primarily in non-hypertensive
patient populations and those with significant cardiovas-
cular co-morbidities) [27–29].
6 Pharmacological Treatment Recommendations
All guidelines recommend four main drug classes for the
treatment of hypertension: angiotensin-converting enzyme
inhibitors (ACEI), angiotensin receptor blockers (ARB),
calcium channel blockers (CCB) and diuretics. As the main
benefits of antihypertensive treatments are due to the
lowering of BP per se and are independent of the specific
drugs utilised, it is accepted that there is no need to dif-
ferentiate between drugs within each class [7]. The advice
regarding the use of b-blockers for the general hyperten-
sive population is variable; the ESH/ESC, French and
China guidelines recommend their use [7, 9, 11]; the JNC
8, NICE and ASH/ISH guidelines recommend them as an
additional drug if BP cannot be controlled with the other
drug classes [3, 5, 8]; Taiwan and AHA/ACC/CDC
guidelines only recommend their use in specific patient
groups (as discussed below) [4, 10]. In addition, based on
the findings of the Medical Research Council (MRC) study
of antihypertensives for the elderly, where b-blockers were
found to be less effective at preventing CV events com-
pared with diuretics [30], CHEP recommends they are only
used in the initial treatment of those under 60 years of age
[6]. These discrepancies in the recommended use of b-
blockers are due to evidence from some trials suggesting
that they are less effective than other drug classes at
Table 4 Blood pressure target levels cited by each guideline across







C60 years \150/90 JNC 8
C65 years \150/90 China
C80 years \150/90 ASH/ISH, ESH/ESC,
France, NICE, CHEP
Diabetes \130/80 CHEP, China, Taiwan
\140/85 ESH/ESC
CKD \130/80 China, Taiwan, ESH/ESCb
Other high-risk patients
e.g., with coronary
disease, history of stroke
\130/80 Taiwan, Chinac
AHA/ACC/CDC American Hypertension Association/American Col-
lege of Cardiology/Centers for Disease Control and Prevention, ASH/
ISH American Society of Hypertension/International Society of
Hypertension, CHEP Canadian hypertension education program,
ESH/ESC European Society of Hypertension/European Society of
Cardiology, JNC 8 Eighth Joint National Committee, NICE National
Institute for Clinical Excellence (UK), CKD chronic kidney disease,
DBP diastolic blood pressure, SBP systolic blood pressure
a The French guidelines suggest a target range of 130–139 mmHg for
SBP
b In patients with proteinuria
c For CHD patients only
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Table 5 Non-pharmacological interventional strategies by guideline [3–11, 26]
Guidelines What is recommended?
JNC 8 Not specifically addressed, but supports the recommendations of the 2013 Lifestyle Work Group, a set of diet
and activity guidelines to reduce CV disease risk [26]
ASH/ISH Weight loss in patients who are overweight or obese
Reduce salt intake
Regular exercise as part of the daily routine
Reduce alcohol consumption—Up to 2 drinks a day for men and 1 for women
Stopping smoking
AHA/ACC/CDC Maintain BMI 18.5–24.9 kg/m2
Consume a diet rich in fruits, vegetables and low-fat dairy products with a reduced content of saturated and total
fat
Consume no more than 2,400 mg sodium/day. Further reduction of sodium intake to 1,500 mg/day is desirable
since it is associated with even greater reduction in BP. Reduce intake by at least 1,000 mg/day since that will
lower BP, even if the desired daily sodium intake is not achieved
Engage in regular aerobic physical activity such as brisk walking at least 30 min per day, most days of the week
Limit alcohol consumption to no more than 2 drinks per day in most men, and no more than 1 drink per day in
women and lighter weight persons
CHEP Physical exercise: 30–60 min moderate intensity dynamic exercise 4–7 days a week
Weight reduction: target BMI 18.5–24.9 kg/m2 and waist circumference \102 cm for men and \88 cm for
women
Alcohol consumption: two drinks or less per day, with consumption not exceeding 14 or 9 standard drinks per
week for men and women, respectively (standard drink is considered 17.2 ml ethanol)
Diet: consume a diet that emphasises fruits, vegetables, low-fat dairy products, dietary and soluble fibre, whole
grains and protein from plant sources that is reduced in saturated fat and cholesterol
Reduce sodium intake towards 5 g of salt daily
Supplementation of potassium, calcium and magnesium is not recommended
Stress management
ESH/ESC Salt reduction
Moderation of alcohol consumption, no more than 20–30 g ethanol per day in men and 10–20 g in women
Consume a diet of vegetables, fruits and low-fat dairy products, dietary and soluble fibre, whole grains and
proteins from plant sources
Reduce consumption of saturated fat and cholesterol
Weight reduction for overweight or obese patients
Regular physical exercise, 30–60 min moderate intensity dynamic exercise 5–7 days a week
Cessation of smoking
France Reduce excessive salt consumption
Regular physical activity
Reduce weight if overweight
Reduce excessive consumption of alcohol
Adopt a diet rich in fruit and vegetables
Cease smoking
NICE Provide diet and exercise advice
Reduce alcohol consumption
Reduce consumption of coffee and caffeine-rich products
Reduce salt intake
Cease smoking
Calcium, magnesium and potassium supplements are not recommended
Relaxation therapies
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controlling BP, not as effective in preventing stroke or
other CV events [31], and due to many of the drugs being
associated with adverse effects such as reduced sexual
function, fatigue, reduced exercise tolerance, increase in
body weight and increased incidence of new onset diabetes
[5, 7, 10].
The guidelines principally base their recommendations
on classes of drugs and do not make intraclass differences
between antihypertensives. Notably, the NICE recom-
mendations preferentially recommend indapamide and
chlorthalidone ahead of thiazide diuretics [8]. This
approach has been questioned in the ESH reappraisal of
their recommendations [7]. In regards to b-blockers none
of the guidelines deal with the issue of whether there are
significant intraclass differences between b-blockers, for
example, whether newer b-blockers like nebivolol or car-
vedilol may be superior to older generation drug [32–34].
Other less frequently recommended classes of drugs,
which are generally only recommended for specific
patient groups, include a-blockers, direct vasodilators,
mineralocorticoid receptor antagonist and a-2 agonists.
The use of direct vasodilators such as hydralazine and
minoxidil is only discussed in the ASH/ISH guidelines,
which suggests they should only be considered as a
fourth-line or later addition to the treatment regimen as
they often cause adverse effects, such as fluid retention
and tachycardia [5].
The guidelines are all in agreement that patient adher-
ence is critical to achieving BP control. To aid this, it is
important that the simplest treatment regimen is utilised to
establish and maintain persistence. As such, longer-acting
drugs that only require once-daily dosing are preferred [3–
11]. Patient education is also a recognised factor in
achieving a high level of persistence; the French guidelines
reinforce this by recommending patients have a consulta-
tion dedicated to providing disease and treatment infor-
mation prior to commencing drug treatment [9].
Personalised treatment regimens are required to enhance
adherence; therefore, to meet the individual’s needs it is
important to account for issues regarding tolerability and
efficacy when deciding on the optimum treatment regimen.
To aid this, the guidelines provide flexible treatment regi-
mens for the general hypertensive population and specific
guidelines influenced by the age, ethnicity and other clin-
ical characteristics of the patient (e.g., diabetes, coronary
disease, etc.) associated with hypertension.
All guidelines under review recognise that reaching BP
control as soon as possible is essential for gaining patient
confidence in the treatment and improving adherence. The
majority of guidelines under review do not specify a
timeframe for achieving BP control [3, 4, 6–8, 10, 11];
however, the ASH/ISH guidelines state that an effective
treatment regimen should be established within 6–8 weeks
of initiating treatment [5], while the French guidelines
recommend that an appropriate treatment regimen be
established within 6 months of initiating treatment [9].
Once an effective treatment regimen is established, the
guidelines all recommend self-monitoring of BP to be used
in combination with regular clinical visits to maintain
patient persistence with drug and health behaviour changes,
and to enable monitoring of treatment efficacy and adverse
effects [3–11].
Table 5 continued










Reduction of body weight
Reduction in alcohol consumption
Increase dietary potassium
Increase physical activity
AHA/ACC/CDC American Hypertension Association/American College of Cardiology/Centers for Disease Control and Prevention, ASH/ISH
American Society of Hypertension/International Society of Hypertension, CHEP Canadian hypertension education program, ESH/ESC European
Society of Hypertension/European Society of Cardiology, JNC 8 Eighth Joint National Committee, NICE National Institute for Clinical
Excellence (UK), BMI body mass index, BP blood pressure, CV cardiovascular
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6.1 Treatment Algorithms
With the exception of the French guidelines, which chose
to focus on a target timeframe for BP control and a specific
triple therapy if needed, all the guidelines discussed
include a treatment algorithm (summarised in Table 6 [3–
11]). In the case of the AHA/ACC/CDC advisory, the
treatment algorithm and its development are the principal
outcomes of the advisory [4].
The treatment algorithms were designed to provide a
simplified treatment guide to be used as a tool by clinicians
to facilitate and aid standardisation of treatment. They are
seen as an effective, concise method of communicating the
guidelines to both healthcare practitioners and patients. All
the algorithms provide guidance based on the patients
initial BP except for JNC 8, which uses goal BP to cate-
gorise patients. Some algorithms further sub-divide patient
groups based on other risk factors such as age, race and
comorbidities.
There are several examples of other successful hyper-
tension treatment algorithms. For example, the Simplified
Treatment Intervention to Control Hypertension (STITCH)
algorithm developed in Canada is thought to have resulted
in a 12 % absolute (20 % relative) improvement in the
proportion of clinical practices reaching target BP com-
pared with practices implementing the usual guideline care
[35]. In addition, the Kaiser Permanente algorithm, a tool
utilised in a wider system-level approach to manage
hypertension, is thought to have played an important role in
achieving the highest BP control rate (85 %) in the world
[36].
7 Treatment Regimens for the General Population
The level of detail provided in the treatment regimens
varies between the guidelines, with some specifying a
precise order in which the drugs should be prescribed
whereas others make more general recommendations
(Table 7). With the exception of the French, NICE and
JNC 8 guidelines, the other guidelines under review rec-
ommend commencing pharmacological treatment in
patients with stage 1 hypertension with one antihyperten-
sive therapy and stage 2 patients with two therapies [4–7,
10, 11]. The French and NICE guidelines both recommend
commencing treatment of stage 2 patients with one anti-
hypertensive therapy [8, 9]. Whereas, the JNC 8 guidelines
state that at the physician’s discretion, the treatment of both
stage 1 and 2 patients can be initiated with either one or
two therapies, as there is not sufficient evidence to support
a specific dosing strategy [3].
The JNC 8, ESH/ESC, CHEP, Taiwan and China
guidelines do not advise on a definitive order in which the
drug classes should be prescribed [3, 6, 7, 10, 11].
Although the NICE and AHA/ACC/CDC guidelines pro-
vide drug class-specific recommendations, there is no
Table 6 Treatment algorithms [3–11]
Guidelines Patient characteristics Treatment recommendations
JNC 8 Patients categorised based on age, goal BP, race
and patients with diabetes/CKD
Specifies drug classes to be used as first-line treatment and longer-term
follow-up treatment options if BP remains uncontrolled
ASH/ISH Patients categorised based on BP and other factors
e.g., age, race, comorbidities
Specifies drug class to be used as first-line treatment and longer-term
follow-up treatment options if BP remains uncontrolled
AHA/ACC/CDC Patients categorised based on stage of hypertension Suggests drug classes to be used, monitoring and follow-up options
CHEP Provides algorithms for diagnosis and treatment Specifies drug classes to be used as first-line treatment and longer-term
follow-up treatment options if BP remains uncontrolled
ESH/ESC Patients categorised based on low or high risk Describes steps to be taken in moving to a more intensive therapy
through dose titration or adding more drugs
No recommendations on drug classes or doses
France No algorithm provided n/a
NICE Diagnosis and treatment algorithms. Treatment
algorithm categorised based on age and race
Recommends drug classes to be used for initial therapy and drug
combinations to be considered if BP remains uncontrolled
Taiwan Patients categorised based on BP and non-high risk
or high risk
Specifies the number of drugs to be prescribed but not specific drug
classes or doses
China Patients categorised based on BP and risk
assessment
Specifies drug classes to be used as first-line treatment and longer-term
follow-up treatment options if BP remains uncontrolled
AHA/ACC/CDC American Hypertension Association/American College of Cardiology/Centers for Disease Control and Prevention, ASH/ISH
American Society of Hypertension/International Society of Hypertension, CHEP Canadian hypertension education program, ESH/ESC European
Society of Hypertension/European Society of Cardiology, JNC 8 Eighth Joint National Committee, NICE National Institute for Clinical
Excellence (UK), BP blood pressure, CKD chronic kidney disease, n/a not applicable
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consensus on which class of drug is best for initiating
therapy; AHA/ACC/CDC recommends a thiazide diuretic
[4], whereas the French guidelines recommend an ACEI or
ARB (due to improved persistence) [9]. The NICE guide-
lines suggests a CCB (for patients [55 years of age or
black) or an ACEI or ARB (for patients aged \55 years)
[8]. In this respect, the ASH/ISH guidelines are very similar
to NICE and recommend the use of a CCB or thiazide for
patients aged C60 years or black, and an ACEI or ARB for
those aged \60 years [5]. The lack of a consensus on the
antihypertensive drug class for initiating treatment reflects
the absence of conclusive clinical evidence to demonstrate
that a specific drug class is superior [3, 7].
As there are no RCTs to support an optimal dosing
strategy, with the exception of the ASH/ISH and JNC 8
guidelines there are no recommended dosing strategies
provided by the guidelines under review [3–11]. The
ASH/ISH guidelines suggest that the initial dose of a
drug should be at least half of the maximum recom-
mended dose, so that only one up-titration is required to
reach the maximum recommended level [5]. JNC 8
guidelines provide three suggested dosing strategies: (1)
start one drug, titrate to maximum dose then add a
second drug; (2) start one drug, then add a second drug
before achieving maximal dose of the first drug; or (3)
begin with two drugs at the same time, either as two
separate pills or as a single pill combination. Never-
theless, JNC 8 panel members emphasise such dosing
strategies are discretionary, and that the final decision
should be left to the clinician and patient [3].
Table 7 Preferred treatment options for general population by guideline
Guidelines Initial treatment Two-drug combinations Three-drug combinations
JNC 8 Thiazide diuretic, CCB, ACEI or ARB Add a drug from another class: thiazide
diuretic, CCB, ACEI or ARB
CCB ? thiazide ? ACEI or ARB
Alone or in combination
ASH/ISH Stage 1: ACEI or ARB CCB or thiazide ? ACEI or ARB CCB ? thiazide ? ACEI or ARB




Stage 1: Thiazide for most patients or ACEI,
ARB, CCB
Add a drug from another class, either,
thiazide diuretic, CCB, ACEI or ARB
Not specified
Stage 2: Thiazide ? ACEI, ARB or CCB
OR ACEI ? CCB
CHEP Thiazide, b-blocker, ACEI, ARB, CCB Add a drug from another class, either,
thiazide, b-blocker, CCB, ACEI or
ARB
Not specified
Consider combination if SBP C20 mmHg
or DBP C10 mmHg above target
ESH/ESC Stage 1: Diuretics, ACEI, ARB, CCB or b-
blocker
Preferred combinations:
Thiazide ? ARB or ACEI
Thiazide ? CCB
CCB ? ARB or ACEI
Add a drug from another class: thiazide
diuretic, CCB, ACEI, ARB or b-
blockerStage 2: 2 drugs
France Initiating treatment with ARB or ACEI
(better persistence versus diuretic or b-
blocker)
Add a drug from another class: thiazide,
b-blocker, CCB, ACEI or ARB.
CCB ? thiazide ? ACEI or ARB
CCB (for adherence) is preferred versus
diuretic or b-blocker
NICE \55 years, ACEI or ARB CCB ? ACEI or ARB CCB ? thiazide ? ACEI or ARB
[55 years CCB
Taiwan Stage 1: Thiazide diuretic, CCB, ARB or
ACEI
ACEI or ARB ? CCB or thiazide CCB ? thiazide ? ACEI or ARB
Stage 2: 2 drugs
China Stage 1: Thiazide diuretic, CCB, ARB,
ACEI or b-blocker
Stage 2: SPCs of 2 drugs
CCB ? ACEI or ARB
OR ACEI or ARB ? thiazide
OR CCB ? thiazide.
OR CCB ? b-blocker
CCB ? ACEI or ARB ? thiazide
OR CCB ? ACEI or ARB ? b-blocker
OR ACEI or ARB ? thiazide ?
a- blocker
AHA/ACC/CDC American Hypertension Association/American College of Cardiology/Centers for Disease Control and Prevention, ASH/ISH
American Society of Hypertension/International Society of Hypertension, CHEP Canadian hypertension education program, ESH/ESC European
Society of Hypertension/European Society of Cardiology, JNC 8 Eighth Joint National Committee, NICE National Institute for Clinical
Excellence (UK), ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, SPC single
pill combination
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Another factor considered by some of the guidelines is
suggested timeframes for adjusting treatments (either
altering the dose or adding additional drugs) until BP is
controlled. The JNC 8, ASH/ISH, AHA/ACC/CDC, ESH/
ESC and CHEP guidelines recommend dose and antihy-
pertensive treatments should be reviewed and modified
every 2–4 weeks until an appropriate regimen is estab-
lished [3–7]. The French guidelines suggest a similar
timeframe, with review consultations provided once a
month [9].
Although all the guidelines acknowledge that the major-
ity of patients will require multiple drugs to gain BP control,
there is no overall consensus regarding which drug combi-
nations are most effective. This is due to the lack of clinical
evidence available, as although trials have shown that
combining drugs from two classes improves BP control [37]
and patient adherence [7, 38], there are few trials which have
compared the effectiveness of different drug combinations
[7]. A summary of the preferred drug combinations is pre-
sented in Table 7. An interesting observation is that there
seems to be a consensus forming between the guidelines,
where the supporting evidence and clinical experience has
led to the majority of guidelines preferring an ACEI or ARB
combined with a CCB, or indeed a thiazide diuretic [3, 5, 7,
8, 10]. The only drug combination that is advised against by
all guidelines is combining ACEI and ARB, due to the
increased risk of end-stage renal disease and stroke identi-
fied by the ONTARGET (an ARB in combination with an
ACEI) [39] and ALTITUDE (direct renin inhibitor, aliski-
ren, in combination with ACEI or ARB) studies, which
investigated the effect of dual renin-angiotensin-aldosterone
system (RAAS) blockade in patients already undergoing
treatment for hypertension [40]. In addition, the ESH/ESC,
ASH/ISH, French and Taiwan guidelines also recommend
caution when prescribing thiazides with b-blockers as this
combination has been associated with an increased risk of
developing diabetes [5, 7, 9, 10].
When three drugs are required to achieve BP control, the
French, NICE, JNC 8, Taiwan and ASH/ISH guidelines all
recommend combining ACEI/ARB with a CCB and a
diuretic [8, 9]. The China guidelines agree with this but
also suggest additional possible combinations such as an a-
blocker in combination with an ACEI/ARB and a diuretic
[11]. The NICE guidelines suggest that a-blockers should
be considered for use in triple therapy if other classes are
not effective or not tolerated [8]. The ESH/ESC, ASH/ISH
and CHEP guidelines do not specify a preferred triple drug
combination [5–7].
7.1 Use of Single Pill Combinations (SPC)
SPCs are recognised as having an important role in the
control of BP as they reduce the number of pills to be
taken, thereby simplifying the treatment regimen, and
improving patient adherence [41]. Analysis of RCTs has
shown that early use of SPCs (including as first-line ther-
apy) may enhance BP control [42]. With the exception of
NICE and AHA/ACC/CDC guidelines—where SPCs are
not mentioned—all guidelines discussed, and both the
STITCH and Kaiser Permanente algorithms, recommend
using SPCs to some extent [3, 5–7, 9–11, 35, 36]. However,
there are some differences in the setting in which they are
mentioned; for example, China and Taiwan guidelines
specifically recommend that SPCs are used for initial
treatment should more than one drug be required [10, 11],
whereas the French guidelines recommend their use if BP
is not controlled within one month of commencing treat-
ment [9]. Moreover, the ASH/ISH guidelines state that
SPCs can be used to simplify treatment but with the pro-
viso that they may be more expensive than other agents [5].
This is in contrast to the Taiwan guidelines which state that
SPCs are always cheaper than the individual component
drugs [10]; a claim which is supported by studies that have
analysed the cost effectiveness of SPCs in the USA [43,
44]. These studies have shown that drug, ambulatory, and
hospital costs are all significantly lower for patients pre-
scribed SPCs compared with loose dose combinations [43,
44]. With an increasing range of both two and three drug
SPCs becoming available, the increasing flexibility of this
form of treatment is likely to facilitate their further use [7],
although issues regarding their cost and lack of data from
clinical trials still remain to be overcome.
8 Treatment Recommendations for Specific Patient
Groups
All guidelines recognise that specific treatment advice is
required for selected populations with different require-
ments to the general population due to age, ethnicity and
comorbidities; Table 8 summarises these recommendations
[3–11].
The ASH/ISH, ESH/ESC, JNC 8, NICE and CHEP
guidelines all recommend initiating treatment of black
patients with either a CCB or thiazide diuretic as there is
evidence [principally from the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack (ALLHAT)
study] that ACEI are less effective for this group [3, 5–8,
45, 46]. The China, Taiwan, AHA/ACC/CDC and French
guidelines did not provide any specific advice for black
patients [9–11, 36].
Although there are no RCTs investigating the treatment
of hypertension during pregnancy, the ESH/ESC, NICE
(provided in a separate set of guidelines entitled ‘Hyper-
tension in Pregnancy’ [47]) ASH/ISH, China and Taiwan
guidelines provide specific recommendations for this group
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based on expert opinion [5, 7, 8, 10, 11]. In addition to the
recommended use of CCBs (specifically, nifedipine in the
ESH/ESC and NICE guidelines [7, 47]) and b-blockers
(specifically, labetatol, as atenolol has been associated with
foetal growth retardation [7, 10, 47]; Table 8), the a-2-
adrenergic agonist, a-methyldopa, is recommended by the
ASH/ISH, ESH/ESC, NICE, Taiwan and Chinese guide-
lines [5, 7, 10, 11, 47] and hydralazine is recommended by
the NICE guidelines [47]. The Taiwan, NICE and ESH/
ESC guidelines state that ACEI and ARBs should not be
used because of their teratogenicity and diuretics should be
avoided in women with reduced plasma volume [7, 8, 10,
47].
The NICE and ASH/ISH guidelines are the only
guidelines with specific drug recommendations for older
patients (those [55 years in NICE and C60 years ASH/
ISH). Both these guidelines recommend commencing
treatment with a CCB or thiazide diuretic in the older
population as opposed to an ACEI or ARB in the younger
population [5, 8].
All the guidelines emphasise the importance of taking
into consideration other comorbidities when determining
the optimal form of treatment. For example, JNC 8
guidelines stipulate that for patients with CKD (regardless
of race or diabetes status), the initial or add-on antihyper-
tensive treatment should include an ACEI or ARB to
improve kidney outcomes (4). This recommendation is also
supported by the Taiwan, CHEP, ASH/ISH, ESH/ESC,
China and JNC 8 guidelines [3, 5–7, 10, 11].
In patients with a history of myocardial infarction, heart
failure or angina pectoris, b-blocker use has been found to
be highly effective in preventing CV events [48]. To reflect
this (although not recommended by many of the guidelines
for the treatment of the general population) b-blockers are
specifically recommended for use in these patient groups
by the ESH/ESC, Taiwan, China, ASH/ISH, AHA/ACC/
CDC, CHEP and NICE guidelines [4–8, 10, 11].
The ESH/ESC, Taiwan, NICE and ASH/ISH guidelines
each provide guidance for patients with resistant hyper-
tension [5, 7, 8, 10]. In addition to advising on the need to
Table 8 Recommended therapies specified by each guideline for specific populations [3–11]
Anhypertensive treatment




























































Black squares refer to initial therapy recommendations; grey squares refer to 2nd line therapy recommendations
C CHEP, T Taiwan, A ASH/ISH, E ESH/ESC, J JNC8, N NICE, CH China, AH AHA/ACC/CDC, F France, AHA/ACC/CDC American
Hypertension Association/American College of Cardiology/Centers for Disease Control and Prevention, ASH/ISH American Society of Hyper-
tension/International Society of Hypertension, CHEP Canadian hypertension education program, ESH/ESC European Society of Hypertension/
European Society of Cardiology, JNC 8 Eighth Joint National Committee, NICE National Institute for Clinical Excellence (UK), ACEI angiotensin
converting enzyme inhibitor, AF atrial fibrillation, ARB angiotensin receptor blocker, CCB calcium channel blocker, ESRD end-stage renal disease,
ISH isolated systolic hypertension
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identify the underlying cause of resistant hypertension (e.g.
sleep apnoea, improper BP monitoring, poor patient
adherence, additional pharmacological treatments which
may exacerbate hypertension or reduce the effectiveness of
anti-hypertensive drugs), the guidelines recommend health
care practitioners to support the patient in implementing
lifestyle modifications, adjust their current antihypertensive
medications as appropriate, and add a mineralocorticoid
antagonist, such as spironolactone to the prescribed medi-
cations [5, 7, 8, 10]. As an alternative form of treatment,
renal denervation is briefly discussed in the ESH/ESC
guidelines [7]. Both the ESH/ESC guidelines and a position
paper published by the ESH conclude that at present there
is insufficient understanding of what factors determine
whether the procedure is likely to be successful and they
state that there is insufficient safety and efficacy evidence
from RCTs to form any recommendations [7, 49]. This has
been highlighted by the recent publication of Simplicity
HTN-3, which in contrast to previous studies [27, 49, 50]
has found that renal denervation does not reduce BP in
patients with resistant hypertension [50]. As such, much
more research is required to fully understand the role of
this controversial form of treatment.
9 Conclusions
Treatment guidelines provide an essential bridge in com-
municating up-to-date information from clinical trials to
clinicians, so that they in turn can provide the best form of
treatment for patients. Despite being produced by a number
of different organisations from around the world, the
guidelines presented in this review [3–11] share many
common recommendations in alignment with the existing
evidence base within this large therapy area. The revised
guidelines recently released by the Japanese Society of
Hypertension (JSH) are also generally in alignment with
those discussed in detail in this review [51]. However, one
of the principal differences is that the JSH recommend
relatively aggressive treatment of elderly hypertensive
patients, due to the particularly high incidence of stroke in
the Japanese population. Indeed, the guidelines recommend
a threshold of C140/90 mmHg for initiating treatment of
the elderly and a BP target of \150/90 mmHg (or \140/
90 mmHg if tolerated) for patients [75 years old [51].
Across the guidelines, the BP target for the elderly is one of
the main areas where no consensus has been reached and it
is certainly an area that would benefit from further clinical
evidence to establish the optimal targets for this group.
Where disparities in the recommendations do exist, it is
generally due to a lack of consistent evidence from clinical
trials. Some of the guidelines, such as the ESH/ESC and
NICE guidelines highlight this problem and prompt for
gaps in the data to be addressed by posing questions (e.g.
‘Should elderly patients with a SBP between 140 and
160 mmHg be given antihypertensive drug treatments?’
[7]) which, should they be answered, would in turn
strengthen future recommendations [7, 8]. We have already
discussed gaps in data concerning age, however, racial
differences, are also not adequately addressed in the current
evidence base that shapes these guidelines. Indeed, current
evidence largely examines hypertension management in
Caucasian populations, which may not be transposable to
Asian and black populations, for example. An exception to
this is the recommendation to initiate treatment of black
patients with either a CCB or thiazide diuretic, principally
based on evidence from the ALLHAT subgroup analysis
[3, 5–8, 45, 46]. If greater consideration is placed on racial
differences in future studies, differences in recommenda-
tions observed across national guidelines may widen. A
separate limitation is that there is little consideration for the
different structures in healthcare systems (e.g. accessibility,
funding) during the development of guidelines that could
limit their ease in adoption into clinical practice.
9.1 Expert Opinion
9.1.1 Guideline Implementation and Impact
Although guidelines themselves are useful tools, proactive
steps and strategies for their successful implementation are
essential to maximise their benefit. Although all the
guidelines presented here were developed by independent
associations, government endorsement, credible leadership
from clinical practitioners and support from the pharma-
ceutical industry are required in their implementation.
Once implemented it is also critical that their outcome and
impact are monitored to help inform and leverage future
changes.
Countries have different problems to overcome in
implementing guidelines. For example, in France where BP
control is no longer a major government priority, one of the
major challenges is the lack of government backing and
financial support. Whereas, in the UK, although the NICE
guidelines were developed independently, they have gained
government support and are aligned with the government
performance managed health policy [quality outcomes
framework (QOF)], a scheme to improve the quality of care
through providing financial incentives to general practi-
tioners. The QOF system both incentivises clinicians and
has generated an electronic database that can be used to
monitor BP control rates and measure the impact of new
interventions. In England, BP control rates have steadily
improved; in 2011, 66 % of men and 61 % of women
receiving treatment for hypertension were classified as
having controlled BP [52].
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It is difficult to accurately assess the impact of imple-
menting guidelines, however, there is some evidence that
suggests guidelines are proving beneficial. For example,
since the launch of CHEP in 1999, 66 % of patients with
hypertension now have controlled BP (compared with
13 % before CHEP), physician visits have doubled, anti-
hypertensive use has tripled, and the decline in hyperten-
sion-related CV complications has accelerated [53]. This is
despite CHEP being a voluntary initiative that makes rec-
ommendations independent of government influence.
Although this has advantages, such as not having to take
into account economic factors, it does create difficulties in
leveraging the recommendations. One of the strategies
taken to overcome this is the development of an interactive
website to widely disseminate the recommendations.
In the USA, one of the factors contributing to poor BP
control is thought to be the fragmented healthcare system
and a lack of standardised guidelines and national imple-
mentation strategies. The creation of a national consensus
guideline that combines both hypertension and other CVD
guidelines to create an integrated strategy may be advan-
tageous [54]. Once guidelines have been agreed upon it
will be necessary to translate these into a specific set of
performance measures, to incentivise their use, and moni-
tor the progress made towards targets [54]. The success of
the Kaiser Permanente initiative in California is thought to
be due to several key elements including: a comprehensive
hypertension registry, development and sharing of perfor-
mance metrics, evidence-based guidelines, medical assis-
tant visits for BP measurement and SPC pharmacotherapy
[36]. Implementing a similar health system approach on a
nationwide scale could be beneficial.
9.1.2 Future Development of Guidelines
To maintain their value and credibility and prevent inertia,
it is essential that guidelines are steadily evolved to keep
up to date with advancements in the subject. Guidelines
should principally be developed by healthcare experts in
the field, however, the involvement of patients in the pro-
cess may add value (as exemplified by the NICE
guidelines).
Guidelines are required to be evidence based and identify
best practises through impartial evaluation of the available
data. The resulting guidelines should be simple to follow and
straightforward to implement. They must provide flexible
recommendations, which consider the country’s unique
healthcare system, to both enable their implementation across
a wide range of clinical practices and to facilitate patient
specific personalisation of treatment.
A key message when considering guidelines for hyper-
tension management is that they demonstrate evidence-
based evolution, not revolution. Indeed, we need to
consider that guidelines or recommendations need evolving
steadily in order to gain confidence in the changes taking
place.
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